Evidence based review of management of cardiorenal syndrome type 1

Table 5 Changes in clinical parameters of the included studies

Intervention	Clinical parameters evaluated
	Ref.	Creatinine (mg/dL)		Change in BUN (mg/dL)		Cystatin C (mg/L)		Weight loss (kg)		Cumulative urine volume (mL)
		Baseline	Mean changes	Baseline	Mean changes	Baseline	Mean changes	Baseline	Mean changes
Dopamine/dobutamine	Chen et al[13], 2013 (dopamine)	1.59	0.00	NA	NA	1.71	0.12	NA	NA	8524
	Chen et al[13], 2013 (placebo)	1.63	0.02	NA	NA	1.66	0.11	NA	NA	8296
	Ref.	Creatinine (mg/dL)		Change in BUN (mg/dL)		RBF (mL/min)		GFR (mL/min)		FF
		Baseline	Treatment	Baseline	Treatment	Baseline	Treatment	Baseline	Treatment	Baseline	Treatment
	Lannemyr et al[15], 2018 (dobutamine)	NA	NA	NA	NA	397 ± 121	499 ± 154	47.1 ± 14.5	47.3 ± 16.9	0.193 ± 0.070	0.161 ± 0.075

BUN: Blood urea nitrogen; FF: filtration fraction; GFR: glomerular filtration rate; NA: Not available; RBF: renal blood flow.